Benzinga | Jul 21, 2021 06:55AM EDT

SVB Leerink Maintains Outperform on Ascendis Pharma, Lowers Price Target to $178

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $181 to $178.